<span item_type="fundamental" item_id="fb1d03268a79c78dc524102679d23ec5" counter_id="ST/US/RMSL" env="prod"></span><span item_type="announcement" item_id="515751976899255169" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 0.</p><p>EPS: As of FY2025 Q1, the actual value is USD 0.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -131.32 K.</p><p></p><h3>Segment Revenue</h3><ul><li>Revenue for the three months ended March 31, 2025 was $0, compared to $57,881 for the same period in 2024, due to the cessation of CPAP machine sales and the upcoming launch of the DeltaWave product.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1412126/000121390025042723/ea0241497-10q_remsleep.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the three months ended March 31, 2025 was - $85,488, compared to - $252,580 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1412126/000121390025042723/ea0241497-10q_remsleep.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses decreased from $168,506 in 2024 to $131,315 in 2025, with notable reductions in general and administrative expenses and development expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1412126/000121390025042723/ea0241497-10q_remsleep.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was - $110,096 for the three months ended March 31, 2025, compared to - $113,475 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1412126/000121390025042723/ea0241497-10q_remsleep.htm"></span></li><li><strong>Financing Cash Flow</strong>: Cash provided by financing activities was $154,000 for the three months ended March 31, 2025, compared to $125,000 for the same period in 2024, primarily from convertible note issuances.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1412126/000121390025042723/ea0241497-10q_remsleep.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Derivative Liability</strong>: The derivative liability increased to $183,854 as of March 31, 2025, from $152,014 as of December 31, 2024, due to new issuances and mark-to-market adjustments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1412126/000121390025042723/ea0241497-10q_remsleep.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to conduct clinical trials for the DeltaWave product and aims to capture 10% of the market in the next 24 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1412126/000121390025042723/ea0241497-10q_remsleep.htm"></span></li><li><strong>Going Concern</strong>: There is substantial doubt regarding the company’s ability to continue as a going concern due to insufficient cash flow from revenue, with plans to obtain funding from new investors and implement a sales generation plan.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1412126/000121390025042723/ea0241497-10q_remsleep.htm"></span></li></ul>

REMSleep Holdings, Inc. | 10-Q: FY2025 Q1 Revenue: USD 0